Natural Capsules is currently trading at Rs. 128.50, up by 5.40 points or 4.39% from its previous closing of Rs. 123.10 on the BSE.
The scrip opened at Rs. 126.00 and has touched a high and low of Rs. 129.20 and Rs. 120.10 respectively. So far 22981 shares were traded on the counter.
The BSE group 'T ' stock of face value Rs. 10 has touched a 52 week high of Rs. 130.70 on 06-Aug-2015 and a 52 week low of Rs. 61.65 on 12-Jun-2015.
Last one week high and low of the scrip stood at Rs. 129.20 and Rs. 112.00 respectively. The current market cap of the company is Rs. 74.73 crore.
The promoters holding in the company stood at 48.54% while Institutions and Non-Institutions held 0.07% and 51.39% respectively.
Natural Capsules has received an approval for enhancement of manufacturing capacity of Gelatin Capsules at its Pondicherry unit from present capacity of 6.1 billion to 8.36 billion capsules per annum by modification of existing manufacturing lines at an approximate cost of Rs 10 crore. The project will be implemented over the next 30 months and will be funded through internal accruals. The board of directors at their meeting held on October 29, 2015 has approved for the same.
The board has also approved the up gradation of manufacturing facility at Bangalore and conversion of existing three gelatin capsules lines there to HPMC (Vegetarian) capsules lines, with a capacity of 1.2 billion capsules at an approximate cost of Rs 15 crore. This is proposed to be funded through a combination of internal accruals & debt and will be implemented over a period of next 30 months.
Further, the company is presently operating at a capacity utilization of around 95% and hence the proposed capacity expansion is to cater to market requirements.
Natural Capsules is a well-equipped modern manufacturing plant to manufacture hard gelatin capsule shells, Hard cellulose capsule shells and pharmaceutical dosage forms in capsule dosage form.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: